Financials
Financial year 2025
NL PHARMA from Florennes, company number BE0661907808, closed financial year 2025 with a result of € -1,457 after tax. For that financial year NL PHARMA recorded a gross margin of € 7,229 and equity of € 4,488. Compared with financial year 2024, the result moved from € 4,242 to € -1,457. The company made a loss. The buffer shrank hard: equity is 85 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.
€ 4,488
▼ 85% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1,457
▼ still € 4,242 profit in 2024
Profit after tax over the fiscal year.
€ 107
▲ 272% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1,712.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 89
▼ 74% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 12,210
▲ 101% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 6,060
▼ 80% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 40,300 | € 20,869 | € 20,551 | € 7,229 | ▼ 65% |
| Profit after taxes | € 16,694 | € -5,763 | € 4,242 | € -1,457 | ▼ € 5,698 |
| Equity | € 46,819 | € 31,758 | € 30,363 | € 4,488 | ▼ 85% |
| Total debts | € 39,135 | € 51,968 | € 47,889 | € 29,270 | ▼ 39% |
| Cash | € 3,719 | € 3,881 | € 29 | € 107 | ▲ 272% |
| Retained profit | € 40,619 | € 25,558 | € 24,163 | € -1,712 | ▼ € 25,875 |
| Dividend | € 9,118 | € 9,298 | € 5,636 | € 24,418 | ▲ € 18,782 |
| Bank debt | € 12,649 | € 4,739 | € 0 | € 0 | |
| Balance sheet total | € 85,953 | € 83,726 | € 78,252 | € 33,758 | ▼ 57% |
Key figures of NL PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NL PHARMA?
What happened at NL PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1,457 (▼ € 5,698 vs 2024). filed late Source: NBB ↗
- New establishment in Florennes. KBO
- Nicolas LESTARQUY became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 16,694 profit in 2022 to € 1,457 loss in 2025.
Paid € 15,257 in corporate taxes since 2022.
Best year ever: 2022, with € 16,694 profit.
Paid out € 48,471 in dividends to the owners in total.
A new publication or filing at NL PHARMA? We notify you, reason included.
Follow NL PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Nicolas LESTARQUY
Director
since 2016
Establishments
Establishment units
Physical locations of this company
Allée des Fougères, Morialmé 412
5620 Florennes
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0661.907.808
- VAT number
- BE 0661.907.808
- Registered office
- Allée des Fougères, Morialmé 412, 5620 Florennes
- Names & denominations
- NL PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 1 September 2016
- Peppol
- Active · Active since 1 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten